The global transfection reagents & equipment market size is expected to reach USD 2.19 billion by 2030, registering a CAGR of 7.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The latest polymeric formulations-based compounds are gentle to cells as compared to cationic liposomes and these products render higher gene-delivery efficiency, further promoting the development of unique transfection products in the market.
Moreover, multi-component reagents such as X-tremeGENE provided by F. Hoffmann-La Roche AG, deliver high efficiency and minimal cytotoxicity than traditional ones comprising only one-component formulations. Thus, companies are keen on offering cutting-edge transfection solutions, in turn, offering significant momentum to market growth.
The gene expression studies segment dominated the market and account for the largest revenue share in 2019. This is attributed to the rising focus on the translation of genomic information in clinics. In addition, an increasing number of research projects related to the identification of chromosomal anomalies is anticipated to propel segment growth.
Request a free sample copy or view report summary: Transfection Reagents & Equipment Market Report
The reagents segment dominated the transfection reagents and equipment market, with the largest revenue share of 55.4% in 2023.
The electroporation segment dominated the market in 2023. The broad selection of electroporation solutions from well-known and up-and-coming companies is driving growth in the segment.
The biomedical research segment is expected to register the fastest CAGR over the forecast period. In recent times, there has been a significant focus on the use of lentivirus for transfection in biomedical research.
North America dominated with largest revenue share in the transfection reagents and equipment market in 2023. The region is expected to continue this pattern in the forecast time frame.
Market participants are keen on expanding their product portfolios aimed at sustaining market competition.
For instance, in July 2019, Mirus Bio launched TransIT-VirusGEN SELECT Transfection Reagent, intended to be used in the drug discovery process in gene and cell manufacturing. The substance simplifies the qualifying process of ancillary materials employed in viral vectors manufacturing for preclinical and early-phase clinical trials.
Grand View Research has segmented the global transfection reagents & equipment market on the basis of on product, method, application, end-use, and region:
Transfection Reagents & Equipment Product Outlook (Revenue, USD Million, 2018 - 2030)
Reagents
Equipment
Transfection Reagents & Equipment Method Outlook (Revenue, USD Million, 2018 - 2030)
Electroporation
Liposomes
Particle Bombardment
Microinjection
Adenoviral Vectors
Calcium Phosphate
DEAE-dextran
Magnetic Beads
Activated Dendrimers
Laserfection
Transfection Reagents & Equipment Application Outlook (Revenue, USD Million, 2018 - 2030)
Gene Expression Studies
Protein Production
Transgenic Models
Therapeutic Delivery
Cancer Research
Biomedical Research
Transfection Reagents & Equipment End-use Outlook (Revenue, USD Million, 2018 - 2030)
Academic And Research Institutes
Pharmaceutical And Biotechnology Companies
Transfection Reagents & Equipment Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Transfection Reagents & Equipment Market
Thermo Fisher Scientific Inc.
Promega Corporation
Lonza
QIAGEN
F. Hoffmann-La Roche Ltd.
Bio-Rad Laboratories, Inc.
Merck KGaA
OriGene Technologies, Inc.
MaxCyte
Polyplus
"The quality of research they have done for us has been excellent..."